Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment
OPEN Clinical and molecular hepatology | 29 May 2020
CH Lee, YB Lee, MA Kim, H Jang, H Oh, SW Kim, EJ Cho, KH Lee, JH Lee, SJ Yu, JH Yoon, TY Kim and YJ Kim
Several treatment options are currently available for patients with hepatocellular carcinoma (HCC) failing previous sorafenib treatment. We aimed to compare the effectiveness of regorafenib and nivolumab in these patients.
* Data courtesy of Altmetric.com